Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors (ENERGY)
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Nateglinide 120 mg
Acarbose 50 mg
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring diabetes mellitus, type 2, nateglinide, acarbose, hyperglycemia, dyslipidemias, C-reactive protein
Eligibility Criteria
Inclusion Criteria:
- Newly diagnosed type 2 diabetes mellitus patients
- HbA1c > 6.5 and < 9.0%
- Fasting fingertip capillary blood glucose (FCBG) < 9 mmol/L after 2 weeks diet control
Exclusion Criteria:
- History of acute metabolic complications in the past 3 months or of severe diabetic complications or severe infections or active substance abuse
- Liver disease
- Patients under oral hypoglycemic drugs and/or insulin treatment, or corticosteroid treatment within past 4 weeks
Other protocol-defined inclusion/exclusion criteria applied to the study.
Sites / Locations
- People's Liberation Army. The Military General Hospital of BeiJing
- Peiking University First Hospital
- Chinese PLA General Hospital
- The First Affiliated Hospital, Zhongshan (Sun Yat-sen) University
- The Second Affiliated Hospital, Zhongshan (Sun Yat-sen) University
- Nanfang Hospital, the Affiliated South Hospital of the Southern Medical University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Nateglinide 120 mg
Acarbose 50 mg
Arm Description
Nateglinide was taken orally 3 times daily, 10 minutes before meals for 4 weeks.
Acarbose 50 mg was taken orally 3 times daily, with the first bite of food at meals for 4 weeks.
Outcomes
Primary Outcome Measures
Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4)
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. PPGE was defined as the mean difference between the preprandial glucose value and the postprandial glucose value measured at 2 hours in a standardized meal test. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
Secondary Outcome Measures
Change From Baseline in Peak Postprandial Glucose at the End of the Study (Week 4)
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The peak postprandial glucose values were used in the calculation of change from Baseline at Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
Change From Baseline in Postprandial Glucose Area Under the Curve at the End of the Study (Week 4)
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The postprandial glucose area under the curve was calculated using values from the 4 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
Change From Baseline in Total Cholesterol at the End of the Study (Week 4)
Blood samples were collected for measurement of total cholesterol prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. Total cholesterol was assessed at each study site using the same method and same reference value.
Change From Baseline in Triglycerides at the End of the Study (Week 4)
Blood samples were collected for measurement of triglycerides prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. Triglycerides were assessed at each study site using the same method and same reference value.
Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the End of the Study (Week 4)
Blood samples were collected for measurement of LDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. LDL-C was assessed at each study site using the same method and same reference value.
Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study (Week 4)
Blood samples were collected for measurement of HDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. HDL-C was assessed at each study site using the same method and same reference value.
Change From Baseline in Free Fatty Acids (FFA) at the End of the Study (Week 4)
Blood samples were collected for measurement of FFA prior to (fasting) and 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. FFA was assayed at a central laboratory.
Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at the End of the Study (Week 4)
Blood samples were collected for measurement of hsCRP prior to (fasting) and 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. hsCRP was assayed at a central laboratory.
Change From Baseline in Glycosylated Serum Albumin (GSA) at the End of the Study (Week 4)
Blood samples were collected for measurement of GSA prior to (fasting) the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. GSA was assayed at a central laboratory.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00928889
Brief Title
Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
Acronym
ENERGY
Official Title
A Multi-center, Open-label, Randomized, Active-control, Parallel-group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug-naive Type 2 Diabetes Mellitus Patients
Study Type
Interventional
2. Study Status
Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
June 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals
4. Oversight
5. Study Description
Brief Summary
This study was conducted to demonstrate superiority of nateglinide in postprandial glucose fluctuation, dyslipidemia, and inflammatory status improvement.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
diabetes mellitus, type 2, nateglinide, acarbose, hyperglycemia, dyslipidemias, C-reactive protein
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
160 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Nateglinide 120 mg
Arm Type
Experimental
Arm Description
Nateglinide was taken orally 3 times daily, 10 minutes before meals for 4 weeks.
Arm Title
Acarbose 50 mg
Arm Type
Active Comparator
Arm Description
Acarbose 50 mg was taken orally 3 times daily, with the first bite of food at meals for 4 weeks.
Intervention Type
Drug
Intervention Name(s)
Nateglinide 120 mg
Other Intervention Name(s)
Starlix
Intervention Description
Nateglinide 120 mg was supplied as tablets.
Intervention Type
Drug
Intervention Name(s)
Acarbose 50 mg
Other Intervention Name(s)
Glucobay
Intervention Description
Acarbose 50 mg was supplied as tablets.
Primary Outcome Measure Information:
Title
Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4)
Description
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. PPGE was defined as the mean difference between the preprandial glucose value and the postprandial glucose value measured at 2 hours in a standardized meal test. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
Time Frame
Baseline to the end of the study (Week 4)
Secondary Outcome Measure Information:
Title
Change From Baseline in Peak Postprandial Glucose at the End of the Study (Week 4)
Description
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The peak postprandial glucose values were used in the calculation of change from Baseline at Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
Time Frame
Baseline to the end of the study (Week 4)
Title
Change From Baseline in Postprandial Glucose Area Under the Curve at the End of the Study (Week 4)
Description
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The postprandial glucose area under the curve was calculated using values from the 4 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.
Time Frame
Baseline to the end of the study (Week 4)
Title
Change From Baseline in Total Cholesterol at the End of the Study (Week 4)
Description
Blood samples were collected for measurement of total cholesterol prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. Total cholesterol was assessed at each study site using the same method and same reference value.
Time Frame
Baseline to the end of the study (Week 4)
Title
Change From Baseline in Triglycerides at the End of the Study (Week 4)
Description
Blood samples were collected for measurement of triglycerides prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. Triglycerides were assessed at each study site using the same method and same reference value.
Time Frame
Baseline to the end of the study (Week 4)
Title
Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the End of the Study (Week 4)
Description
Blood samples were collected for measurement of LDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. LDL-C was assessed at each study site using the same method and same reference value.
Time Frame
Baseline to the end of the study (Week 4)
Title
Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study (Week 4)
Description
Blood samples were collected for measurement of HDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. HDL-C was assessed at each study site using the same method and same reference value.
Time Frame
Baseline to the end of the study (Week 4)
Title
Change From Baseline in Free Fatty Acids (FFA) at the End of the Study (Week 4)
Description
Blood samples were collected for measurement of FFA prior to (fasting) and 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. FFA was assayed at a central laboratory.
Time Frame
Baseline to the end of the study (Week 4)
Title
Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at the End of the Study (Week 4)
Description
Blood samples were collected for measurement of hsCRP prior to (fasting) and 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. hsCRP was assayed at a central laboratory.
Time Frame
Baseline to the end of the study (Week 4)
Title
Change From Baseline in Glycosylated Serum Albumin (GSA) at the End of the Study (Week 4)
Description
Blood samples were collected for measurement of GSA prior to (fasting) the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. GSA was assayed at a central laboratory.
Time Frame
Baseline to the end of the study (Week 4)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Newly diagnosed type 2 diabetes mellitus patients
HbA1c > 6.5 and < 9.0%
Fasting fingertip capillary blood glucose (FCBG) < 9 mmol/L after 2 weeks diet control
Exclusion Criteria:
History of acute metabolic complications in the past 3 months or of severe diabetic complications or severe infections or active substance abuse
Liver disease
Patients under oral hypoglycemic drugs and/or insulin treatment, or corticosteroid treatment within past 4 weeks
Other protocol-defined inclusion/exclusion criteria applied to the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
People's Liberation Army. The Military General Hospital of BeiJing
City
BeiJing
ZIP/Postal Code
100020
Country
China
Facility Name
Peiking University First Hospital
City
BeiJing
ZIP/Postal Code
100034
Country
China
Facility Name
Chinese PLA General Hospital
City
Beijing
ZIP/Postal Code
100853
Country
China
Facility Name
The First Affiliated Hospital, Zhongshan (Sun Yat-sen) University
City
Guangzhou
ZIP/Postal Code
510080
Country
China
Facility Name
The Second Affiliated Hospital, Zhongshan (Sun Yat-sen) University
City
Guangzhou
ZIP/Postal Code
510120
Country
China
Facility Name
Nanfang Hospital, the Affiliated South Hospital of the Southern Medical University
City
Guangzhou
ZIP/Postal Code
510515
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
17376293
Citation
Gao HW, Xie C, Wang HN, Lin YJ, Hong TP. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes. Acta Pharmacol Sin. 2007 Apr;28(4):534-9. doi: 10.1111/j.1745-7254.2007.00534.x.
Results Reference
background
Learn more about this trial
Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
We'll reach out to this number within 24 hrs